Galimedix Therapeutics Inc. has commenced dosing in a Phase 1 clinical trial evaluating oral GAL-101, an amyloid beta (Aβ) aggregation modulator. The study is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of the orally administered therapy.
Trial Objectives
The primary objective of the Phase 1 trial is to determine the safety and tolerability of GAL-101 in healthy volunteers. Secondary endpoints include evaluating the pharmacokinetic profile of the drug to understand how it is absorbed, distributed, metabolized, and excreted by the body. This information is crucial for determining appropriate dosing in future clinical trials.
GAL-101: A Novel Approach to Amyloid Beta Modulation
GAL-101 represents a novel therapeutic approach by targeting the aggregation of amyloid beta, a key pathological hallmark in several diseases. By modulating Aβ aggregation, GAL-101 aims to prevent the formation of toxic oligomers and plaques that contribute to neuronal damage and cognitive decline.
Tenpoint Therapeutics and Visus Therapeutics Merge
Tenpoint Therapeutics Ltd. and Visus Therapeutics Inc. have completed their merger, consolidating their respective ophthalmic therapeutic assets. The new entity aims to address ocular conditions related to aging, with a focus on presbyopia, cataracts, and geographic atrophy. A central component of the merged portfolio is BRIMOCHOL PF, a once-daily, presbyopia-correcting eye drop, which combines carbachol, a miotic agent, with brimonidine, an alpha2-agonist.
Diffusion Optics Technology Shows Promise in Myopia Control
Results from a recent 4-year study indicate that Diffusion Optics Technology (DOT) 0.2 spectacle lenses (SightGlass Vision) are safe and effective for reducing myopia progression in young children. The lenses demonstrated an additional benefit in the fourth year of wear, supporting the hypothesis that a mild reduction in retinal contrast can slow myopia progression.
